ArticleACS omega2026
IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression and Is Associated with MAPK Signaling and Macrophage-Related Immune Features.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is an mRNA-binding protein implicated in tumorigenesis across multiple cancer types, but its functional role in oral squamous cell carcinoma (OSCC) remains incompletely understood. In this study, we combined bioinformatic analyses, validation in clinical specimens and cell lines, and functional experiments to investigate the role of IGF2BP2 in OSCC. IGF2BP2 was significantly elevated in OSCC and associated with poor overall survival. This upregulation was further validated in patient tissues and OSCC cell lines by quantitative real-time PCR, Western blot, and immunohistochemistry. IGF2BP2 knockdown markedly suppressed OSCC cell proliferation and migration in vitro and inhibited tumor growth in xenograft models in vivo. In parallel, IGF2BP2 depletion resulted in reduced phosphorylation of ERK and p38, supporting an association between IGF2BP2 and MAPK signaling activity in OSCC. In addition, immune-related pathway enrichment and immune infiltration analyses further suggested links between IGF2BP2 and the OSCC tumor immune microenvironment. Flow cytometric analysis of xenograft tumors revealed that IGF2BP2 knockdown altered macrophage-related immune features, including a reduced proportion of CD86
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.